Relay Therapeutics to Present Zovegalisib Data from 20 Vascular Anomaly Patients May 19-22
Relay Therapeutics will present initial clinical results from ~20 efficacy-evaluable adult and pediatric PIK3CA-driven vascular anomaly patients treated with zovegalisib at the ISSVA World Congress May 19-22. Zovegalisib, an allosteric mutant-selective PI3Kα inhibitor in Phase 3 breast cancer and Phase 1/2 vascular anomaly studies, addresses ~310,000 US patients annually.
1. Presentation at ISSVA World Congress
Relay Therapeutics will present initial clinical results and preclinical data for zovegalisib at the ISSVA World Congress 2026 in Philadelphia from May 19 to 22, with a late-breaking clinical abstract session on May 20 and a preclinical session on May 22.
2. Clinical Study Details
The clinical presentation covers initial efficacy data from approximately 20 adult and pediatric patients with PIK3CA-driven vascular malformations treated with zovegalisib, while preclinical research demonstrates lesion regression and minimal hyperinsulinemia in murine models.
3. Mechanism of Zovegalisib
Zovegalisib is the first allosteric pan-mutant selective PI3Kα inhibitor discovered using the Dynamo® platform, leveraging cryo-EM structural insights and molecular dynamics to selectively target mutant over wild-type PI3Kα.
4. Ongoing Trials and Market Potential
Beyond vascular anomalies, zovegalisib is in a Phase 3 trial for HR+/HER2- metastatic breast cancer and a Phase 1/2 vascular anomalies study, potentially addressing an estimated 140,000 breast cancer and 170,000 vascular anomaly patients annually in the US.